Navigation Links
Xlumena Receives CE Mark for Revolutionary AXIOS™ Stent and Delivery System
Date:5/5/2011

MOUNTAIN VIEW, Calif., May 5, 2011 /PRNewswire/ -- Xlumena, Inc., a privately-held provider of innovative technology for the interventional endoscopist and endoscopic surgeon, announced today that it has received CE Mark approval for its revolutionary AXIOS™ Stent and Delivery System (AXIOS). The AXIOS is the first stent designed for endoscopic ultrasound-guided translumenal therapy and is indicated for drainage of pancreatic pseudocysts. Having achieved this important milestone, Xlumena will begin a targeted commercial launch of the AXIOS in select European markets.  

"The AXIOS Stent opens up a frontier of new treatments in and around the gastrointestinal tract.  Not only does the AXIOS Stent create a large, secure drainage pathway – equivalent to a surgical anastomosis – it also provides an access port to pass the endoscope into the duct or lumen cavity for targeted therapy.  This technology has the potential to expand the role of endoscopy in treating a variety of disorders of the pancreatic and biliary system," stated Kenneth Binmoeller, MD, Director of Interventional Endoscopy Services at California Pacific Medical Center in San Francisco, California.

Unlike tubular stents used for bile and pancreatic duct drainage, the AXIOS Stent is designed to hold two lumens in apposition for translumenal drainage.  The bilateral anchors of the AXIOS Stent prevent movement and migration and the large-diameter Stent lumen ensures drainage.   The AXIOS is fully covered to prevent leakage across the stent and tissue ingrowth and facilitate removal.  The AXIOS Stent comes pre-loaded in a specially-designed Delivery System and is easily deployed by a single operator.

"AXIOS leverages the expertise and vision of the interventional endoscopy community. It represents a new frontier in endoscopic therapy that uses ultrasound to guide intervention outside of the gastrointestinal tract. This avoids more invasive treatments such as surgery," commented Michael Allen, Xlumena's President and CEO.  "Xlumena is committed to advancing endoscopic treatment options through the development of safe, efficient and easy to use technologies."

About the AXIOS Stent and Delivery System

The AXIOS Stent is fully-covered, self-expandable and available in multiple lumen diameters (15mm, 10mm, 8mm and 6mm) and lengths (10mm, 6mm and 4mm) to ensure a custom fit. The Delivery System is ergonomic and allows the interventional endoscopist to control and precisely deliver the AXIOS to the intended target using a single hand. To view an animation of the AXIOS Stent and Delivery System, visit http://www.vimeo.com/xlumena/axios

About Xlumena

Xlumena is the leader in the development of image-guided therapeutic endoscopy products, specializing in advanced implants and devices for a new, rapidly growing field of medicine. Collaborating with top physicians in the field, Xlumena focuses on technologies that advance therapy to the next level. These innovations may enable numerous translumenal therapeutic procedures, helping transform complex surgeries into outpatient events.

To view an animation of Xlumena's first product, the NAVIX Access Device (FDA cleared), visit http://www.vimeo.com/xlumena/navix

Contact: Witney McKiernan  650.961.9900


'/>"/>
SOURCE Xlumena, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears Xlumenas NAVIX(TM) Access Device
2. Xlumena, Inc. Closes $7M Series B Venture Financing Round
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 24, 2017   QR Pharma , Inc., ... novel therapies for the treatment of Alzheimer,s, Parkinson,s ... of four world-class key opinion leaders to its ... QR Pharma,s previous roster of impressive advisors in ... support the development of the breakthrough mechanism of ...
(Date:1/24/2017)... , January 24, 2017 The global  active ... 239.8 billion by 2025, based on a new report by Grand View ... is projected to drive the market over the forecast period. Advancements in ... also estimated to boost growth.  Continue Reading ... ...
(Date:1/24/2017)... 2017 INTRODUCTION Injectable drug delivery systems ... with vials to prefilled syringes, auto-injectors, pen injectors ... become preferred devices for parenteral administration of drugs. ... rising strongly over the past several years. A ... this format for delivering drugs. The popularity of ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... Bellus Medical, a leader in medical aesthetics, ... In his new role Dr. Dobke will provide physician oversight for in-house clinical studies ... Head of Plastic Surgery and Associate Professor of Surgery at UC San Diego Health ...
(Date:1/24/2017)... ... January 24, 2017 , ... Providing solutions to critical economic ... the Frank Hawkins Kenan Institute of Private Enterprise at the University ... makers identified concrete solutions at the “What’s Next, America?” conference at the Kenan ...
(Date:1/24/2017)... Rosa, CA (PRWEB) , ... January 24, 2017 , ... ... is good news for everyone and particularly good news for prostate cancer patients: incidents ... the diagnosis. , According to the report the cancer death rate has dropped from ...
(Date:1/24/2017)... ... ... American Family Care (AFC) has opened a new 4,000+ square foot state-of-the-art urgent ... area. The Bedford clinic will be the nineteenth location opened by AFC in Massachusetts ... Dr. Kristina Orio. Adams and Orio also independently own and operate AFC clinics in ...
(Date:1/24/2017)... ... January 24, 2017 , ... TopConsumerReviews.com recently ... relieving premenstrual syndrome, or PMS . , Most women of child-bearing age ... include cramps, constipation, irritability, headaches, fatigue, and other discomfort. For some women, ...
Breaking Medicine News(10 mins):